nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—PTGS2—skin cancer	0.316	1	CbGaD
Sulindac—ALB—Vismodegib—skin cancer	0.0804	0.205	CbGbCtD
Sulindac—CYP1A2—Imiquimod—skin cancer	0.0694	0.177	CbGbCtD
Sulindac—CYP1A1—Dacarbazine—skin cancer	0.0652	0.167	CbGbCtD
Sulindac—ALB—Vemurafenib—skin cancer	0.0635	0.162	CbGbCtD
Sulindac—CYP1A2—Vemurafenib—skin cancer	0.038	0.0971	CbGbCtD
Sulindac—CYP1A2—Dacarbazine—skin cancer	0.0291	0.0745	CbGbCtD
Sulindac—ALB—Fluorouracil—skin cancer	0.0285	0.073	CbGbCtD
Sulindac—CYP1A2—Fluorouracil—skin cancer	0.0171	0.0436	CbGbCtD
Sulindac—MAPK3—endothelium—skin cancer	0.00363	0.0527	CbGeAlD
Sulindac—MAPK3—blood vessel—skin cancer	0.00334	0.0486	CbGeAlD
Sulindac—AKR1B1—nipple—skin cancer	0.00333	0.0485	CbGeAlD
Sulindac—PTGDR2—female reproductive system—skin cancer	0.00314	0.0456	CbGeAlD
Sulindac—MAPK3—nipple—skin cancer	0.00242	0.0351	CbGeAlD
Sulindac—MAPK3—neck—skin cancer	0.00239	0.0348	CbGeAlD
Sulindac—AKR1B1—connective tissue—skin cancer	0.00236	0.0344	CbGeAlD
Sulindac—AKR1B1—epithelium—skin cancer	0.00225	0.0326	CbGeAlD
Sulindac—PTGS2—leg—skin cancer	0.00204	0.0296	CbGeAlD
Sulindac—AKR1B1—mammalian vulva—skin cancer	0.00195	0.0283	CbGeAlD
Sulindac—PTGS2—hindlimb—skin cancer	0.00182	0.0264	CbGeAlD
Sulindac—AKR1B1—lymphoid tissue—skin cancer	0.00173	0.0251	CbGeAlD
Sulindac—MAPK3—connective tissue—skin cancer	0.00171	0.0249	CbGeAlD
Sulindac—AKR1B1—female reproductive system—skin cancer	0.00167	0.0243	CbGeAlD
Sulindac—MAPK3—epithelium—skin cancer	0.00163	0.0237	CbGeAlD
Sulindac—PTGS2—appendage—skin cancer	0.00156	0.0227	CbGeAlD
Sulindac—MAPK3—skin of body—skin cancer	0.00155	0.0225	CbGeAlD
Sulindac—CYP1A1—skin epidermis—skin cancer	0.00155	0.0225	CbGeAlD
Sulindac—PPARD—mammalian vulva—skin cancer	0.00153	0.0223	CbGeAlD
Sulindac—MAPK3—mammalian vulva—skin cancer	0.00141	0.0205	CbGeAlD
Sulindac—AKR1B1—head—skin cancer	0.00139	0.0203	CbGeAlD
Sulindac—PPARD—lymphoid tissue—skin cancer	0.00136	0.0198	CbGeAlD
Sulindac—PPARD—female reproductive system—skin cancer	0.00131	0.0191	CbGeAlD
Sulindac—PTGS2—skin epidermis—skin cancer	0.0013	0.0189	CbGeAlD
Sulindac—MAPK3—lymphoid tissue—skin cancer	0.00125	0.0182	CbGeAlD
Sulindac—MAPK3—female reproductive system—skin cancer	0.00121	0.0176	CbGeAlD
Sulindac—PPARD—head—skin cancer	0.0011	0.0159	CbGeAlD
Sulindac—MAPK3—head—skin cancer	0.00101	0.0147	CbGeAlD
Sulindac—PTGS1—endothelium—skin cancer	0.000985	0.0143	CbGeAlD
Sulindac—AKR1B1—lymph node—skin cancer	0.000976	0.0142	CbGeAlD
Sulindac—PTGS2—endothelium—skin cancer	0.000942	0.0137	CbGeAlD
Sulindac—PTGS1—blood vessel—skin cancer	0.000909	0.0132	CbGeAlD
Sulindac—PTGS2—blood vessel—skin cancer	0.000869	0.0126	CbGeAlD
Sulindac—PPARD—lymph node—skin cancer	0.000767	0.0112	CbGeAlD
Sulindac—CYP1A2—nipple—skin cancer	0.000758	0.011	CbGeAlD
Sulindac—CYP1A1—nipple—skin cancer	0.000748	0.0109	CbGeAlD
Sulindac—MAPK3—lymph node—skin cancer	0.000707	0.0103	CbGeAlD
Sulindac—PTGS1—nipple—skin cancer	0.000657	0.00955	CbGeAlD
Sulindac—CYP1A1—epithelium—skin cancer	0.000503	0.00732	CbGeAlD
Sulindac—CYP1A1—skin of body—skin cancer	0.000479	0.00696	CbGeAlD
Sulindac—PTGS1—connective tissue—skin cancer	0.000466	0.00677	CbGeAlD
Sulindac—PTGS2—connective tissue—skin cancer	0.000445	0.00647	CbGeAlD
Sulindac—PTGS1—epithelium—skin cancer	0.000442	0.00643	CbGeAlD
Sulindac—CYP1A1—mammalian vulva—skin cancer	0.000437	0.00635	CbGeAlD
Sulindac—PTGS2—epithelium—skin cancer	0.000423	0.00615	CbGeAlD
Sulindac—PTGS1—skin of body—skin cancer	0.000421	0.00612	CbGeAlD
Sulindac—PTGS2—skin of body—skin cancer	0.000402	0.00585	CbGeAlD
Sulindac—PTGS1—mammalian vulva—skin cancer	0.000384	0.00558	CbGeAlD
Sulindac—CYP1A1—female reproductive system—skin cancer	0.000374	0.00544	CbGeAlD
Sulindac—ALB—lymph node—skin cancer	0.000337	0.0049	CbGeAlD
Sulindac—Hyperglycaemia—Temozolomide—skin cancer	0.000332	0.00284	CcSEcCtD
Sulindac—Pneumonia—Temozolomide—skin cancer	0.000331	0.00282	CcSEcCtD
Sulindac—PTGS1—female reproductive system—skin cancer	0.000329	0.00478	CbGeAlD
Sulindac—Depression—Temozolomide—skin cancer	0.000328	0.0028	CcSEcCtD
Sulindac—Hepatitis—Dactinomycin—skin cancer	0.000326	0.00278	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000326	0.00278	CcSEcCtD
Sulindac—PTGS2—lymphoid tissue—skin cancer	0.000326	0.00473	CbGeAlD
Sulindac—Flushing—Bleomycin—skin cancer	0.000325	0.00277	CcSEcCtD
Sulindac—Body temperature increased—Vemurafenib—skin cancer	0.000324	0.00277	CcSEcCtD
Sulindac—Pancytopenia—Fluorouracil—skin cancer	0.000322	0.00275	CcSEcCtD
Sulindac—Neuropathy peripheral—Temozolomide—skin cancer	0.000322	0.00275	CcSEcCtD
Sulindac—Stomatitis—Temozolomide—skin cancer	0.00032	0.00274	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000319	0.00272	CcSEcCtD
Sulindac—Insomnia—Imiquimod—skin cancer	0.000316	0.0027	CcSEcCtD
Sulindac—Hepatic failure—Docetaxel—skin cancer	0.000316	0.00269	CcSEcCtD
Sulindac—PTGS2—female reproductive system—skin cancer	0.000314	0.00457	CbGeAlD
Sulindac—Paraesthesia—Imiquimod—skin cancer	0.000314	0.00268	CcSEcCtD
Sulindac—Chills—Bleomycin—skin cancer	0.000314	0.00268	CcSEcCtD
Sulindac—Cardiac failure congestive—Docetaxel—skin cancer	0.000313	0.00267	CcSEcCtD
Sulindac—CYP1A1—head—skin cancer	0.000312	0.00454	CbGeAlD
Sulindac—Dyspnoea—Imiquimod—skin cancer	0.000312	0.00266	CcSEcCtD
Sulindac—Somnolence—Imiquimod—skin cancer	0.000311	0.00265	CcSEcCtD
Sulindac—Photosensitivity reaction—Fluorouracil—skin cancer	0.00031	0.00265	CcSEcCtD
Sulindac—Alopecia—Bleomycin—skin cancer	0.000309	0.00264	CcSEcCtD
Sulindac—Erythema multiforme—Dactinomycin—skin cancer	0.000308	0.00263	CcSEcCtD
Sulindac—Dyspepsia—Imiquimod—skin cancer	0.000308	0.00263	CcSEcCtD
Sulindac—Pneumonia—Fluorouracil—skin cancer	0.000305	0.0026	CcSEcCtD
Sulindac—Decreased appetite—Imiquimod—skin cancer	0.000304	0.0026	CcSEcCtD
Sulindac—Flushing—Dactinomycin—skin cancer	0.000303	0.00258	CcSEcCtD
Sulindac—Hypersensitivity—Vemurafenib—skin cancer	0.000302	0.00258	CcSEcCtD
Sulindac—Fatigue—Imiquimod—skin cancer	0.000302	0.00257	CcSEcCtD
Sulindac—Visual disturbance—Docetaxel—skin cancer	0.000299	0.00256	CcSEcCtD
Sulindac—Renal impairment—Docetaxel—skin cancer	0.000298	0.00254	CcSEcCtD
Sulindac—Neuropathy peripheral—Fluorouracil—skin cancer	0.000297	0.00253	CcSEcCtD
Sulindac—Stomatitis—Fluorouracil—skin cancer	0.000295	0.00252	CcSEcCtD
Sulindac—Hepatitis—Temozolomide—skin cancer	0.000295	0.00252	CcSEcCtD
Sulindac—Conjunctivitis—Fluorouracil—skin cancer	0.000294	0.00251	CcSEcCtD
Sulindac—Asthenia—Vemurafenib—skin cancer	0.000294	0.00251	CcSEcCtD
Sulindac—Chills—Dactinomycin—skin cancer	0.000293	0.0025	CcSEcCtD
Sulindac—Pruritus—Vemurafenib—skin cancer	0.00029	0.00248	CcSEcCtD
Sulindac—Alopecia—Dactinomycin—skin cancer	0.000288	0.00246	CcSEcCtD
Sulindac—Feeling abnormal—Imiquimod—skin cancer	0.000288	0.00246	CcSEcCtD
Sulindac—Gastrointestinal pain—Imiquimod—skin cancer	0.000286	0.00244	CcSEcCtD
Sulindac—Epistaxis—Fluorouracil—skin cancer	0.000286	0.00244	CcSEcCtD
Sulindac—Visual impairment—Temozolomide—skin cancer	0.000284	0.00243	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000284	0.00242	CcSEcCtD
Sulindac—Agranulocytosis—Fluorouracil—skin cancer	0.000283	0.00241	CcSEcCtD
Sulindac—Ill-defined disorder—Bleomycin—skin cancer	0.000282	0.00241	CcSEcCtD
Sulindac—Anaemia—Bleomycin—skin cancer	0.000281	0.0024	CcSEcCtD
Sulindac—Diarrhoea—Vemurafenib—skin cancer	0.000281	0.0024	CcSEcCtD
Sulindac—Erythema multiforme—Temozolomide—skin cancer	0.000279	0.00238	CcSEcCtD
Sulindac—Urticaria—Imiquimod—skin cancer	0.000278	0.00237	CcSEcCtD
Sulindac—Body temperature increased—Imiquimod—skin cancer	0.000276	0.00236	CcSEcCtD
Sulindac—Tinnitus—Temozolomide—skin cancer	0.000275	0.00235	CcSEcCtD
Sulindac—Malaise—Bleomycin—skin cancer	0.000275	0.00234	CcSEcCtD
Sulindac—PTGS1—head—skin cancer	0.000274	0.00399	CbGeAlD
Sulindac—Flushing—Temozolomide—skin cancer	0.000274	0.00234	CcSEcCtD
Sulindac—Leukopenia—Bleomycin—skin cancer	0.000272	0.00233	CcSEcCtD
Sulindac—Dizziness—Vemurafenib—skin cancer	0.000271	0.00232	CcSEcCtD
Sulindac—Chills—Temozolomide—skin cancer	0.000265	0.00226	CcSEcCtD
Sulindac—Ill-defined disorder—Dactinomycin—skin cancer	0.000263	0.00225	CcSEcCtD
Sulindac—Anaemia—Dactinomycin—skin cancer	0.000262	0.00224	CcSEcCtD
Sulindac—PTGS2—head—skin cancer	0.000262	0.00381	CbGeAlD
Sulindac—Vomiting—Vemurafenib—skin cancer	0.000261	0.00223	CcSEcCtD
Sulindac—Alopecia—Temozolomide—skin cancer	0.000261	0.00223	CcSEcCtD
Sulindac—Chest pain—Bleomycin—skin cancer	0.000259	0.00221	CcSEcCtD
Sulindac—Myalgia—Bleomycin—skin cancer	0.000259	0.00221	CcSEcCtD
Sulindac—Rash—Vemurafenib—skin cancer	0.000259	0.00221	CcSEcCtD
Sulindac—Dermatitis—Vemurafenib—skin cancer	0.000258	0.00221	CcSEcCtD
Sulindac—Hypersensitivity—Imiquimod—skin cancer	0.000258	0.0022	CcSEcCtD
Sulindac—Headache—Vemurafenib—skin cancer	0.000257	0.00219	CcSEcCtD
Sulindac—Discomfort—Bleomycin—skin cancer	0.000256	0.00219	CcSEcCtD
Sulindac—Malaise—Dactinomycin—skin cancer	0.000256	0.00219	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000255	0.00218	CcSEcCtD
Sulindac—Leukopenia—Dactinomycin—skin cancer	0.000254	0.00217	CcSEcCtD
Sulindac—Dysgeusia—Temozolomide—skin cancer	0.000251	0.00215	CcSEcCtD
Sulindac—Asthenia—Imiquimod—skin cancer	0.000251	0.00214	CcSEcCtD
Sulindac—Anaphylactic shock—Bleomycin—skin cancer	0.000248	0.00212	CcSEcCtD
Sulindac—Oedema—Bleomycin—skin cancer	0.000248	0.00212	CcSEcCtD
Sulindac—Pruritus—Imiquimod—skin cancer	0.000247	0.00211	CcSEcCtD
Sulindac—Nausea—Vemurafenib—skin cancer	0.000244	0.00208	CcSEcCtD
Sulindac—Thrombocytopenia—Bleomycin—skin cancer	0.000243	0.00208	CcSEcCtD
Sulindac—Arrhythmia—Fluorouracil—skin cancer	0.000243	0.00207	CcSEcCtD
Sulindac—Vision blurred—Temozolomide—skin cancer	0.000242	0.00207	CcSEcCtD
Sulindac—Myalgia—Dactinomycin—skin cancer	0.000242	0.00206	CcSEcCtD
Sulindac—Bronchospasm—Docetaxel—skin cancer	0.000241	0.00206	CcSEcCtD
Sulindac—Alopecia—Fluorouracil—skin cancer	0.00024	0.00205	CcSEcCtD
Sulindac—Diarrhoea—Imiquimod—skin cancer	0.000239	0.00204	CcSEcCtD
Sulindac—Discomfort—Dactinomycin—skin cancer	0.000239	0.00204	CcSEcCtD
Sulindac—Ill-defined disorder—Temozolomide—skin cancer	0.000238	0.00203	CcSEcCtD
Sulindac—Anaemia—Temozolomide—skin cancer	0.000237	0.00203	CcSEcCtD
Sulindac—Anorexia—Bleomycin—skin cancer	0.000237	0.00202	CcSEcCtD
Sulindac—Angioedema—Temozolomide—skin cancer	0.000235	0.002	CcSEcCtD
Sulindac—Pancytopenia—Docetaxel—skin cancer	0.000233	0.00199	CcSEcCtD
Sulindac—Hypotension—Bleomycin—skin cancer	0.000232	0.00198	CcSEcCtD
Sulindac—Oedema—Dactinomycin—skin cancer	0.000232	0.00198	CcSEcCtD
Sulindac—Malaise—Temozolomide—skin cancer	0.000232	0.00198	CcSEcCtD
Sulindac—Dizziness—Imiquimod—skin cancer	0.000231	0.00197	CcSEcCtD
Sulindac—Vertigo—Temozolomide—skin cancer	0.000231	0.00197	CcSEcCtD
Sulindac—Leukopenia—Temozolomide—skin cancer	0.00023	0.00196	CcSEcCtD
Sulindac—Neutropenia—Docetaxel—skin cancer	0.000229	0.00196	CcSEcCtD
Sulindac—Palpitations—Temozolomide—skin cancer	0.000227	0.00194	CcSEcCtD
Sulindac—Thrombocytopenia—Dactinomycin—skin cancer	0.000227	0.00194	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000226	0.00193	CcSEcCtD
Sulindac—Paraesthesia—Bleomycin—skin cancer	0.000223	0.00191	CcSEcCtD
Sulindac—Vision blurred—Fluorouracil—skin cancer	0.000223	0.0019	CcSEcCtD
Sulindac—Convulsion—Temozolomide—skin cancer	0.000222	0.0019	CcSEcCtD
Sulindac—Vomiting—Imiquimod—skin cancer	0.000222	0.0019	CcSEcCtD
Sulindac—Hypertension—Temozolomide—skin cancer	0.000222	0.00189	CcSEcCtD
Sulindac—Dyspnoea—Bleomycin—skin cancer	0.000222	0.00189	CcSEcCtD
Sulindac—Anorexia—Dactinomycin—skin cancer	0.000221	0.00189	CcSEcCtD
Sulindac—Rash—Imiquimod—skin cancer	0.000221	0.00188	CcSEcCtD
Sulindac—Dermatitis—Imiquimod—skin cancer	0.00022	0.00188	CcSEcCtD
Sulindac—Pneumonia—Docetaxel—skin cancer	0.00022	0.00188	CcSEcCtD
Sulindac—Headache—Imiquimod—skin cancer	0.000219	0.00187	CcSEcCtD
Sulindac—CYP1A1—lymph node—skin cancer	0.000219	0.00318	CbGeAlD
Sulindac—Anaemia—Fluorouracil—skin cancer	0.000219	0.00187	CcSEcCtD
Sulindac—Arthralgia—Temozolomide—skin cancer	0.000219	0.00187	CcSEcCtD
Sulindac—Myalgia—Temozolomide—skin cancer	0.000219	0.00187	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000217	0.00185	CcSEcCtD
Sulindac—Discomfort—Temozolomide—skin cancer	0.000216	0.00184	CcSEcCtD
Sulindac—Decreased appetite—Bleomycin—skin cancer	0.000216	0.00184	CcSEcCtD
Sulindac—Renal failure—Docetaxel—skin cancer	0.000215	0.00183	CcSEcCtD
Sulindac—Neuropathy peripheral—Docetaxel—skin cancer	0.000214	0.00183	CcSEcCtD
Sulindac—Jaundice—Docetaxel—skin cancer	0.000213	0.00182	CcSEcCtD
Sulindac—Stomatitis—Docetaxel—skin cancer	0.000213	0.00182	CcSEcCtD
Sulindac—Conjunctivitis—Docetaxel—skin cancer	0.000212	0.00181	CcSEcCtD
Sulindac—Leukopenia—Fluorouracil—skin cancer	0.000212	0.00181	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000211	0.0018	CcSEcCtD
Sulindac—Anaphylactic shock—Temozolomide—skin cancer	0.00021	0.00179	CcSEcCtD
Sulindac—Oedema—Temozolomide—skin cancer	0.00021	0.00179	CcSEcCtD
Sulindac—Nausea—Imiquimod—skin cancer	0.000208	0.00177	CcSEcCtD
Sulindac—Epistaxis—Docetaxel—skin cancer	0.000206	0.00176	CcSEcCtD
Sulindac—Thrombocytopenia—Temozolomide—skin cancer	0.000205	0.00175	CcSEcCtD
Sulindac—Convulsion—Fluorouracil—skin cancer	0.000205	0.00175	CcSEcCtD
Sulindac—Feeling abnormal—Bleomycin—skin cancer	0.000205	0.00175	CcSEcCtD
Sulindac—Agranulocytosis—Docetaxel—skin cancer	0.000204	0.00174	CcSEcCtD
Sulindac—Hyperhidrosis—Temozolomide—skin cancer	0.000203	0.00173	CcSEcCtD
Sulindac—Chest pain—Fluorouracil—skin cancer	0.000201	0.00172	CcSEcCtD
Sulindac—Myalgia—Fluorouracil—skin cancer	0.000201	0.00172	CcSEcCtD
Sulindac—Decreased appetite—Dactinomycin—skin cancer	0.000201	0.00172	CcSEcCtD
Sulindac—Fatigue—Dactinomycin—skin cancer	0.0002	0.00171	CcSEcCtD
Sulindac—Anorexia—Temozolomide—skin cancer	0.0002	0.00171	CcSEcCtD
Sulindac—Discomfort—Fluorouracil—skin cancer	0.000199	0.0017	CcSEcCtD
Sulindac—Urticaria—Bleomycin—skin cancer	0.000197	0.00169	CcSEcCtD
Sulindac—Body temperature increased—Bleomycin—skin cancer	0.000196	0.00168	CcSEcCtD
Sulindac—Hepatitis—Docetaxel—skin cancer	0.000196	0.00168	CcSEcCtD
Sulindac—Oedema—Fluorouracil—skin cancer	0.000193	0.00165	CcSEcCtD
Sulindac—Anaphylactic shock—Fluorouracil—skin cancer	0.000193	0.00165	CcSEcCtD
Sulindac—PTGS1—lymph node—skin cancer	0.000192	0.00279	CbGeAlD
Sulindac—Feeling abnormal—Dactinomycin—skin cancer	0.000191	0.00163	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000191	0.00163	CcSEcCtD
Sulindac—Insomnia—Temozolomide—skin cancer	0.00019	0.00162	CcSEcCtD
Sulindac—Gastrointestinal pain—Dactinomycin—skin cancer	0.000189	0.00162	CcSEcCtD
Sulindac—Thrombocytopenia—Fluorouracil—skin cancer	0.000189	0.00161	CcSEcCtD
Sulindac—Visual impairment—Docetaxel—skin cancer	0.000189	0.00161	CcSEcCtD
Sulindac—Tachycardia—Fluorouracil—skin cancer	0.000188	0.00161	CcSEcCtD
Sulindac—Paraesthesia—Temozolomide—skin cancer	0.000188	0.00161	CcSEcCtD
Sulindac—Dyspnoea—Temozolomide—skin cancer	0.000187	0.0016	CcSEcCtD
Sulindac—Somnolence—Temozolomide—skin cancer	0.000186	0.00159	CcSEcCtD
Sulindac—Erythema multiforme—Docetaxel—skin cancer	0.000185	0.00158	CcSEcCtD
Sulindac—Dyspepsia—Temozolomide—skin cancer	0.000184	0.00158	CcSEcCtD
Sulindac—Anorexia—Fluorouracil—skin cancer	0.000184	0.00157	CcSEcCtD
Sulindac—PTGS2—lymph node—skin cancer	0.000184	0.00267	CbGeAlD
Sulindac—Body temperature increased—Dactinomycin—skin cancer	0.000183	0.00156	CcSEcCtD
Sulindac—Hypersensitivity—Bleomycin—skin cancer	0.000183	0.00156	CcSEcCtD
Sulindac—Decreased appetite—Temozolomide—skin cancer	0.000182	0.00156	CcSEcCtD
Sulindac—Flushing—Docetaxel—skin cancer	0.000182	0.00155	CcSEcCtD
Sulindac—Fatigue—Temozolomide—skin cancer	0.000181	0.00154	CcSEcCtD
Sulindac—Hypotension—Fluorouracil—skin cancer	0.00018	0.00154	CcSEcCtD
Sulindac—Constipation—Temozolomide—skin cancer	0.000179	0.00153	CcSEcCtD
Sulindac—Asthenia—Bleomycin—skin cancer	0.000178	0.00152	CcSEcCtD
Sulindac—Chills—Docetaxel—skin cancer	0.000176	0.0015	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000176	0.0015	CcSEcCtD
Sulindac—Pruritus—Bleomycin—skin cancer	0.000176	0.0015	CcSEcCtD
Sulindac—Arrhythmia—Docetaxel—skin cancer	0.000175	0.0015	CcSEcCtD
Sulindac—Insomnia—Fluorouracil—skin cancer	0.000175	0.00149	CcSEcCtD
Sulindac—Paraesthesia—Fluorouracil—skin cancer	0.000173	0.00148	CcSEcCtD
Sulindac—Alopecia—Docetaxel—skin cancer	0.000173	0.00148	CcSEcCtD
Sulindac—Feeling abnormal—Temozolomide—skin cancer	0.000173	0.00147	CcSEcCtD
Sulindac—Dyspnoea—Fluorouracil—skin cancer	0.000172	0.00147	CcSEcCtD
Sulindac—Somnolence—Fluorouracil—skin cancer	0.000172	0.00147	CcSEcCtD
Sulindac—Gastrointestinal pain—Temozolomide—skin cancer	0.000171	0.00146	CcSEcCtD
Sulindac—Hypersensitivity—Dactinomycin—skin cancer	0.000171	0.00146	CcSEcCtD
Sulindac—Dyspepsia—Fluorouracil—skin cancer	0.00017	0.00145	CcSEcCtD
Sulindac—Decreased appetite—Fluorouracil—skin cancer	0.000168	0.00143	CcSEcCtD
Sulindac—Dysgeusia—Docetaxel—skin cancer	0.000167	0.00143	CcSEcCtD
Sulindac—Urticaria—Temozolomide—skin cancer	0.000166	0.00142	CcSEcCtD
Sulindac—Asthenia—Dactinomycin—skin cancer	0.000166	0.00142	CcSEcCtD
Sulindac—Body temperature increased—Temozolomide—skin cancer	0.000166	0.00141	CcSEcCtD
Sulindac—Feeling abnormal—Fluorouracil—skin cancer	0.000159	0.00136	CcSEcCtD
Sulindac—Diarrhoea—Dactinomycin—skin cancer	0.000159	0.00135	CcSEcCtD
Sulindac—Vomiting—Bleomycin—skin cancer	0.000158	0.00135	CcSEcCtD
Sulindac—Anaemia—Docetaxel—skin cancer	0.000158	0.00135	CcSEcCtD
Sulindac—Rash—Bleomycin—skin cancer	0.000157	0.00134	CcSEcCtD
Sulindac—Dermatitis—Bleomycin—skin cancer	0.000157	0.00134	CcSEcCtD
Sulindac—Hypersensitivity—Temozolomide—skin cancer	0.000154	0.00132	CcSEcCtD
Sulindac—Urticaria—Fluorouracil—skin cancer	0.000153	0.00131	CcSEcCtD
Sulindac—Syncope—Docetaxel—skin cancer	0.000153	0.00131	CcSEcCtD
Sulindac—Leukopenia—Docetaxel—skin cancer	0.000153	0.00131	CcSEcCtD
Sulindac—Body temperature increased—Fluorouracil—skin cancer	0.000153	0.0013	CcSEcCtD
Sulindac—Palpitations—Docetaxel—skin cancer	0.000151	0.00129	CcSEcCtD
Sulindac—Asthenia—Temozolomide—skin cancer	0.00015	0.00128	CcSEcCtD
Sulindac—Loss of consciousness—Docetaxel—skin cancer	0.00015	0.00128	CcSEcCtD
Sulindac—Pruritus—Temozolomide—skin cancer	0.000148	0.00127	CcSEcCtD
Sulindac—Convulsion—Docetaxel—skin cancer	0.000148	0.00126	CcSEcCtD
Sulindac—Nausea—Bleomycin—skin cancer	0.000148	0.00126	CcSEcCtD
Sulindac—Hypertension—Docetaxel—skin cancer	0.000147	0.00126	CcSEcCtD
Sulindac—Vomiting—Dactinomycin—skin cancer	0.000147	0.00126	CcSEcCtD
Sulindac—Rash—Dactinomycin—skin cancer	0.000146	0.00125	CcSEcCtD
Sulindac—Myalgia—Docetaxel—skin cancer	0.000145	0.00124	CcSEcCtD
Sulindac—Chest pain—Docetaxel—skin cancer	0.000145	0.00124	CcSEcCtD
Sulindac—Arthralgia—Docetaxel—skin cancer	0.000145	0.00124	CcSEcCtD
Sulindac—Diarrhoea—Temozolomide—skin cancer	0.000143	0.00122	CcSEcCtD
Sulindac—Hypersensitivity—Fluorouracil—skin cancer	0.000142	0.00121	CcSEcCtD
Sulindac—Anaphylactic shock—Docetaxel—skin cancer	0.000139	0.00119	CcSEcCtD
Sulindac—Oedema—Docetaxel—skin cancer	0.000139	0.00119	CcSEcCtD
Sulindac—Dizziness—Temozolomide—skin cancer	0.000139	0.00118	CcSEcCtD
Sulindac—Nausea—Dactinomycin—skin cancer	0.000138	0.00118	CcSEcCtD
Sulindac—Shock—Docetaxel—skin cancer	0.000137	0.00117	CcSEcCtD
Sulindac—Pruritus—Fluorouracil—skin cancer	0.000137	0.00117	CcSEcCtD
Sulindac—Thrombocytopenia—Docetaxel—skin cancer	0.000136	0.00117	CcSEcCtD
Sulindac—Tachycardia—Docetaxel—skin cancer	0.000136	0.00116	CcSEcCtD
Sulindac—Vomiting—Temozolomide—skin cancer	0.000133	0.00114	CcSEcCtD
Sulindac—Anorexia—Docetaxel—skin cancer	0.000133	0.00113	CcSEcCtD
Sulindac—Rash—Temozolomide—skin cancer	0.000132	0.00113	CcSEcCtD
Sulindac—Diarrhoea—Fluorouracil—skin cancer	0.000132	0.00113	CcSEcCtD
Sulindac—Dermatitis—Temozolomide—skin cancer	0.000132	0.00113	CcSEcCtD
Sulindac—Headache—Temozolomide—skin cancer	0.000131	0.00112	CcSEcCtD
Sulindac—Hypotension—Docetaxel—skin cancer	0.00013	0.00111	CcSEcCtD
Sulindac—Dizziness—Fluorouracil—skin cancer	0.000128	0.00109	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000127	0.00108	CcSEcCtD
Sulindac—Insomnia—Docetaxel—skin cancer	0.000126	0.00108	CcSEcCtD
Sulindac—Paraesthesia—Docetaxel—skin cancer	0.000125	0.00107	CcSEcCtD
Sulindac—Nausea—Temozolomide—skin cancer	0.000124	0.00106	CcSEcCtD
Sulindac—Dyspnoea—Docetaxel—skin cancer	0.000124	0.00106	CcSEcCtD
Sulindac—Somnolence—Docetaxel—skin cancer	0.000124	0.00106	CcSEcCtD
Sulindac—Vomiting—Fluorouracil—skin cancer	0.000123	0.00105	CcSEcCtD
Sulindac—Dyspepsia—Docetaxel—skin cancer	0.000123	0.00105	CcSEcCtD
Sulindac—Rash—Fluorouracil—skin cancer	0.000122	0.00104	CcSEcCtD
Sulindac—Dermatitis—Fluorouracil—skin cancer	0.000122	0.00104	CcSEcCtD
Sulindac—Decreased appetite—Docetaxel—skin cancer	0.000121	0.00103	CcSEcCtD
Sulindac—Headache—Fluorouracil—skin cancer	0.000121	0.00103	CcSEcCtD
Sulindac—Fatigue—Docetaxel—skin cancer	0.00012	0.00103	CcSEcCtD
Sulindac—Constipation—Docetaxel—skin cancer	0.000119	0.00102	CcSEcCtD
Sulindac—Feeling abnormal—Docetaxel—skin cancer	0.000115	0.000981	CcSEcCtD
Sulindac—Nausea—Fluorouracil—skin cancer	0.000115	0.000979	CcSEcCtD
Sulindac—Gastrointestinal pain—Docetaxel—skin cancer	0.000114	0.000973	CcSEcCtD
Sulindac—Body temperature increased—Docetaxel—skin cancer	0.00011	0.000941	CcSEcCtD
Sulindac—Hypersensitivity—Docetaxel—skin cancer	0.000103	0.000877	CcSEcCtD
Sulindac—Asthenia—Docetaxel—skin cancer	0.0001	0.000854	CcSEcCtD
Sulindac—Pruritus—Docetaxel—skin cancer	9.86e-05	0.000842	CcSEcCtD
Sulindac—Diarrhoea—Docetaxel—skin cancer	9.54e-05	0.000814	CcSEcCtD
Sulindac—Dizziness—Docetaxel—skin cancer	9.22e-05	0.000787	CcSEcCtD
Sulindac—Vomiting—Docetaxel—skin cancer	8.86e-05	0.000757	CcSEcCtD
Sulindac—Rash—Docetaxel—skin cancer	8.79e-05	0.00075	CcSEcCtD
Sulindac—Dermatitis—Docetaxel—skin cancer	8.78e-05	0.00075	CcSEcCtD
Sulindac—Headache—Docetaxel—skin cancer	8.73e-05	0.000746	CcSEcCtD
Sulindac—Nausea—Docetaxel—skin cancer	8.28e-05	0.000707	CcSEcCtD
Sulindac—MAPK3—MyD88:Mal cascade initiated on plasma membrane—IL6—skin cancer	6.21e-05	0.000581	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—NRAS—skin cancer	6.14e-05	0.000574	CbGpPWpGaD
Sulindac—MAPK3—Regulation of Actin Cytoskeleton—NRAS—skin cancer	6.14e-05	0.000574	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC12A2—skin cancer	6.14e-05	0.000574	CbGpPWpGaD
Sulindac—MAPK3—PDGFR-beta signaling pathway—KRAS—skin cancer	6.08e-05	0.000568	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—skin cancer	6.07e-05	0.000567	CbGpPWpGaD
Sulindac—MAPK3—Disease—CSPG4—skin cancer	6.07e-05	0.000567	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—NRAS—skin cancer	6.04e-05	0.000565	CbGpPWpGaD
Sulindac—MAPK3—MyD88-independent cascade—IL6—skin cancer	5.96e-05	0.000557	CbGpPWpGaD
Sulindac—MAPK3—ErbB1 downstream signaling—HRAS—skin cancer	5.94e-05	0.000555	CbGpPWpGaD
Sulindac—MAPK3—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	5.85e-05	0.000547	CbGpPWpGaD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—IL6—skin cancer	5.82e-05	0.000544	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—HRAS—skin cancer	5.81e-05	0.000543	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—BRAF—skin cancer	5.8e-05	0.000542	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—PTGS2—skin cancer	5.78e-05	0.000541	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—NRAS—skin cancer	5.77e-05	0.00054	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—NRAS—skin cancer	5.77e-05	0.000539	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—NRAS—skin cancer	5.74e-05	0.000537	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—NRAS—skin cancer	5.71e-05	0.000534	CbGpPWpGaD
Sulindac—MAPK3—Senescence-Associated Secretory Phenotype (SASP)—IL6—skin cancer	5.69e-05	0.000531	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—NRAS—skin cancer	5.69e-05	0.000531	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—TP53—skin cancer	5.66e-05	0.000529	CbGpPWpGaD
Sulindac—MAPK3—Oxidative Stress Induced Senescence—TP53—skin cancer	5.62e-05	0.000525	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTCH2—skin cancer	5.61e-05	0.000524	CbGpPWpGaD
Sulindac—MAPK3—VEGFA-VEGFR2 Pathway—IL6—skin cancer	5.6e-05	0.000523	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—NRAS—skin cancer	5.58e-05	0.000521	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—IL6—skin cancer	5.56e-05	0.00052	CbGpPWpGaD
Sulindac—MAPK3—Signaling by VEGF—HRAS—skin cancer	5.53e-05	0.000516	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—KRAS—skin cancer	5.52e-05	0.000516	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Insulin receptor—HRAS—skin cancer	5.49e-05	0.000513	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TERT—skin cancer	5.48e-05	0.000512	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	5.38e-05	0.000503	CbGpPWpGaD
Sulindac—MAPK3—Activated TLR4 signalling—IL6—skin cancer	5.36e-05	0.000501	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	5.35e-05	0.0005	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—NRAS—skin cancer	5.35e-05	0.0005	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—NRAS—skin cancer	5.35e-05	0.0005	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—CDKN2A—skin cancer	5.34e-05	0.000499	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—NRAS—skin cancer	5.3e-05	0.000495	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.29e-05	0.000494	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	5.29e-05	0.000494	CbGpPWpGaD
Sulindac—MAPK3—Signaling by VEGF—IL6—skin cancer	5.29e-05	0.000494	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—KRAS—skin cancer	5.28e-05	0.000494	CbGpPWpGaD
Sulindac—MAPK3—Regulation of Actin Cytoskeleton—KRAS—skin cancer	5.28e-05	0.000494	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—NRAS—skin cancer	5.25e-05	0.000491	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Insulin receptor—IL6—skin cancer	5.25e-05	0.000491	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—NRAS—skin cancer	5.23e-05	0.000489	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—KRAS—skin cancer	5.2e-05	0.000486	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—IL6—skin cancer	5.18e-05	0.000484	CbGpPWpGaD
Sulindac—MAPK3—PDGFR-beta signaling pathway—HRAS—skin cancer	5.17e-05	0.000483	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—ERCC2—skin cancer	5.05e-05	0.000472	CbGpPWpGaD
Sulindac—MAPK3—Toll Like Receptor 4 (TLR4) Cascade—IL6—skin cancer	5.04e-05	0.000471	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—KRAS—skin cancer	4.97e-05	0.000464	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—KRAS—skin cancer	4.97e-05	0.000464	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—KRAS—skin cancer	4.94e-05	0.000462	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—KRAS—skin cancer	4.92e-05	0.000459	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—IL6—skin cancer	4.91e-05	0.000459	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—KRAS—skin cancer	4.89e-05	0.000457	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—SHH—skin cancer	4.89e-05	0.000457	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—IL6—skin cancer	4.88e-05	0.000456	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—KRAS—skin cancer	4.8e-05	0.000449	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	4.76e-05	0.000445	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	4.74e-05	0.000443	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PLIN2—skin cancer	4.72e-05	0.000441	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—HRAS—skin cancer	4.69e-05	0.000439	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PTCH1—skin cancer	4.63e-05	0.000433	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—SMO—skin cancer	4.63e-05	0.000433	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—NRAS—skin cancer	4.62e-05	0.000431	CbGpPWpGaD
Sulindac—MAPK3—BDNF signaling pathway—HRAS—skin cancer	4.62e-05	0.000431	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—KRAS—skin cancer	4.6e-05	0.00043	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	4.6e-05	0.00043	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—KRAS—skin cancer	4.6e-05	0.00043	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	4.58e-05	0.000428	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—KRAS—skin cancer	4.56e-05	0.000426	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	4.55e-05	0.000425	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—IL6—skin cancer	4.54e-05	0.000425	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—KRAS—skin cancer	4.52e-05	0.000423	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PTGER4—skin cancer	4.51e-05	0.000422	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—KRAS—skin cancer	4.5e-05	0.000421	CbGpPWpGaD
Sulindac—MAPK3—Toll-Like Receptors Cascades—IL6—skin cancer	4.49e-05	0.00042	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—IL6—skin cancer	4.49e-05	0.00042	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—HRAS—skin cancer	4.49e-05	0.00042	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—HRAS—skin cancer	4.42e-05	0.000413	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CDK4—skin cancer	4.38e-05	0.000409	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TERT—skin cancer	4.38e-05	0.000409	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—BRAF—skin cancer	4.34e-05	0.000405	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TP53—skin cancer	4.33e-05	0.000405	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	4.33e-05	0.000405	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—IL6—skin cancer	4.3e-05	0.000402	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TP53—skin cancer	4.27e-05	0.000399	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GLI2—skin cancer	4.25e-05	0.000397	CbGpPWpGaD
Sulindac—MAPK3—Insulin Signaling—HRAS—skin cancer	4.24e-05	0.000396	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—CDK4—skin cancer	4.23e-05	0.000395	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—IL6—skin cancer	4.23e-05	0.000395	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—HRAS—skin cancer	4.22e-05	0.000395	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—HRAS—skin cancer	4.22e-05	0.000394	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—HRAS—skin cancer	4.2e-05	0.000392	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—HRAS—skin cancer	4.18e-05	0.000391	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—HRAS—skin cancer	4.16e-05	0.000389	CbGpPWpGaD
Sulindac—MAPK3—Disease—ENO2—skin cancer	4.12e-05	0.000385	CbGpPWpGaD
Sulindac—MAPK3—Disease—SHH—skin cancer	4.12e-05	0.000385	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	4.08e-05	0.000381	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MC1R—skin cancer	4.05e-05	0.000379	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—IL6—skin cancer	4.04e-05	0.000378	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—IL6—skin cancer	4.02e-05	0.000376	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—IL6—skin cancer	4e-05	0.000374	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GLI1—skin cancer	3.99e-05	0.000373	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—IL6—skin cancer	3.98e-05	0.000372	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—KRAS—skin cancer	3.97e-05	0.000371	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—IL6—skin cancer	3.97e-05	0.000371	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	3.94e-05	0.000368	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—TP53—skin cancer	3.93e-05	0.000367	CbGpPWpGaD
Sulindac—PPARD—Metabolism—ERCC2—skin cancer	3.93e-05	0.000367	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CDK4—skin cancer	3.92e-05	0.000366	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	3.91e-05	0.000366	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—HRAS—skin cancer	3.91e-05	0.000366	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—HRAS—skin cancer	3.91e-05	0.000366	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—IL6—skin cancer	3.9e-05	0.000364	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—HRAS—skin cancer	3.88e-05	0.000362	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	3.87e-05	0.000362	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	3.85e-05	0.00036	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—HRAS—skin cancer	3.84e-05	0.000359	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—HRAS—skin cancer	3.83e-05	0.000358	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CSPG4—skin cancer	3.81e-05	0.000356	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SUFU—skin cancer	3.79e-05	0.000354	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PLIN2—skin cancer	3.75e-05	0.00035	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—IL6—skin cancer	3.75e-05	0.00035	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	3.75e-05	0.00035	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—IL6—skin cancer	3.75e-05	0.00035	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—IL6—skin cancer	3.71e-05	0.000347	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—NRAS—skin cancer	3.71e-05	0.000346	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—IL6—skin cancer	3.68e-05	0.000344	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—IL6—skin cancer	3.66e-05	0.000342	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—NRAS—skin cancer	3.64e-05	0.00034	CbGpPWpGaD
Sulindac—MAPK3—Immune System—FOXO4—skin cancer	3.64e-05	0.00034	CbGpPWpGaD
Sulindac—PTGS2—Disease—CSPG4—skin cancer	3.61e-05	0.000337	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—IL6—skin cancer	3.6e-05	0.000336	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	3.47e-05	0.000324	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—HRAS—skin cancer	3.38e-05	0.000316	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TP53—skin cancer	3.37e-05	0.000314	CbGpPWpGaD
Sulindac—MAPK3—Disease—FOXO4—skin cancer	3.36e-05	0.000314	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	3.35e-05	0.000313	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CDKN2A—skin cancer	3.35e-05	0.000313	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PLIN2—skin cancer	3.33e-05	0.000311	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	3.32e-05	0.00031	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—NRAS—skin cancer	3.3e-05	0.000308	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—IL6—skin cancer	3.23e-05	0.000302	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	3.21e-05	0.0003	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—KRAS—skin cancer	3.19e-05	0.000298	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—IL6—skin cancer	3.15e-05	0.000294	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—KRAS—skin cancer	3.14e-05	0.000293	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IL6—skin cancer	3.08e-05	0.000288	CbGpPWpGaD
Sulindac—ALB—Metabolism—PLIN2—skin cancer	3.03e-05	0.000283	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CSPG4—skin cancer	3.02e-05	0.000282	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CDKN2A—skin cancer	2.99e-05	0.00028	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—TP53—skin cancer	2.97e-05	0.000278	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SHH—skin cancer	2.89e-05	0.00027	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RASA1—skin cancer	2.87e-05	0.000268	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—KRAS—skin cancer	2.84e-05	0.000265	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTCH1—skin cancer	2.74e-05	0.000256	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SMO—skin cancer	2.74e-05	0.000256	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—NRAS—skin cancer	2.73e-05	0.000255	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—IL6—skin cancer	2.72e-05	0.000254	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HRAS—skin cancer	2.71e-05	0.000253	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CSPG4—skin cancer	2.68e-05	0.000251	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—HRAS—skin cancer	2.67e-05	0.000249	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTGER4—skin cancer	2.67e-05	0.000249	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL6—skin cancer	2.59e-05	0.000242	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ENO2—skin cancer	2.59e-05	0.000242	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—ERCC2—skin cancer	2.58e-05	0.000241	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.58e-05	0.000241	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—IL6—skin cancer	2.55e-05	0.000238	CbGpPWpGaD
Sulindac—PTGS2—Disease—SHH—skin cancer	2.45e-05	0.000229	CbGpPWpGaD
Sulindac—PTGS2—Disease—ENO2—skin cancer	2.45e-05	0.000229	CbGpPWpGaD
Sulindac—ALB—Metabolism—CSPG4—skin cancer	2.44e-05	0.000228	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—HRAS—skin cancer	2.41e-05	0.000225	CbGpPWpGaD
Sulindac—MAPK3—Disease—ERCC2—skin cancer	2.4e-05	0.000224	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTGS2—skin cancer	2.36e-05	0.00022	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FOXO4—skin cancer	2.35e-05	0.00022	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—NRAS—skin cancer	2.35e-05	0.00022	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—KRAS—skin cancer	2.35e-05	0.000219	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—IL6—skin cancer	2.31e-05	0.000216	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—NRAS—skin cancer	2.31e-05	0.000216	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.29e-05	0.000214	CbGpPWpGaD
Sulindac—MAPK3—Disease—TERT—skin cancer	2.25e-05	0.00021	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PLIN2—skin cancer	2.12e-05	0.000198	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—skin cancer	2.09e-05	0.000195	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—NRAS—skin cancer	2.08e-05	0.000194	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ENO2—skin cancer	2.05e-05	0.000192	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—KRAS—skin cancer	2.03e-05	0.000189	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.02e-05	0.000189	CbGpPWpGaD
Sulindac—PTGS2—Disease—FOXO4—skin cancer	2e-05	0.000187	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HRAS—skin cancer	2e-05	0.000186	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—KRAS—skin cancer	1.99e-05	0.000186	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL6—skin cancer	1.91e-05	0.000178	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ENO2—skin cancer	1.82e-05	0.00017	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KRAS—skin cancer	1.79e-05	0.000167	CbGpPWpGaD
Sulindac—MAPK3—Disease—BRAF—skin cancer	1.78e-05	0.000166	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—skin cancer	1.77e-05	0.000165	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—HRAS—skin cancer	1.72e-05	0.000161	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CSPG4—skin cancer	1.71e-05	0.00016	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—HRAS—skin cancer	1.69e-05	0.000158	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—skin cancer	1.67e-05	0.000156	CbGpPWpGaD
Sulindac—ALB—Metabolism—ENO2—skin cancer	1.66e-05	0.000155	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—IL6—skin cancer	1.65e-05	0.000154	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TERT—skin cancer	1.57e-05	0.000147	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HRAS—skin cancer	1.52e-05	0.000142	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ERCC2—skin cancer	1.5e-05	0.00014	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IL6—skin cancer	1.46e-05	0.000136	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTGS2—skin cancer	1.44e-05	0.000134	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.43e-05	0.000133	CbGpPWpGaD
Sulindac—PTGS2—Disease—ERCC2—skin cancer	1.42e-05	0.000133	CbGpPWpGaD
Sulindac—PTGS2—Disease—TERT—skin cancer	1.34e-05	0.000125	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—NRAS—skin cancer	1.32e-05	0.000124	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.3e-05	0.000121	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BRAF—skin cancer	1.25e-05	0.000116	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NRAS—skin cancer	1.21e-05	0.000113	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ERCC2—skin cancer	1.19e-05	0.000111	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ENO2—skin cancer	1.16e-05	0.000109	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—skin cancer	1.14e-05	0.000107	CbGpPWpGaD
Sulindac—MAPK3—Disease—NRAS—skin cancer	1.12e-05	0.000104	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NRAS—skin cancer	1.11e-05	0.000104	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ERCC2—skin cancer	1.06e-05	9.89e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—BRAF—skin cancer	1.06e-05	9.88e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—skin cancer	1.04e-05	9.74e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRAS—skin cancer	9.69e-06	9.06e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ERCC2—skin cancer	9.65e-06	9.02e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—skin cancer	9.62e-06	8.99e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—skin cancer	9.56e-06	8.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—skin cancer	9.28e-06	8.67e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.09e-06	8.49e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—skin cancer	9.01e-06	8.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HRAS—skin cancer	8.86e-06	8.27e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—skin cancer	8.5e-06	7.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—skin cancer	8.48e-06	7.92e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—HRAS—skin cancer	8.18e-06	7.64e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HRAS—skin cancer	8.13e-06	7.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NRAS—skin cancer	7.83e-06	7.31e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—skin cancer	7.83e-06	7.31e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ERCC2—skin cancer	6.75e-06	6.31e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—skin cancer	6.74e-06	6.29e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NRAS—skin cancer	6.65e-06	6.21e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—skin cancer	6.35e-06	5.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—skin cancer	5.99e-06	5.59e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—skin cancer	5.79e-06	5.41e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRAS—skin cancer	5.73e-06	5.35e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—skin cancer	5.72e-06	5.35e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—skin cancer	5.48e-06	5.12e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HRAS—skin cancer	4.86e-06	4.54e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—skin cancer	4.65e-06	4.35e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—skin cancer	4.05e-06	3.78e-05	CbGpPWpGaD
